• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

镭-223 联合阿比特龙治疗的前列腺癌患者发生脆性骨折的风险更高：泼尼松可能是罪魁祸首。

Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit.

机构信息

Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Spedali Civili Hospital, Brescia, Italy.

Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Spedali Civili Hospital, Brescia, Italy.

出版信息

Eur Urol. 2019 Jun;75(6):894-895. doi: 10.1016/j.eururo.2019.01.026. Epub 2019 Jan 31.

DOI:10.1016/j.eururo.2019.01.026
PMID:30711330
Abstract

Results from the ERA 223 trial of abiraterone combined with radium-223 among men with chemotherapy-naïve castration-resistant prostate cancer and bone metastases show no improvement in survival free from symptomatic skeletal events. We hypothesize that this finding might be attributable to bone loss induced by the concomitantly administered prednisone.

摘要

来自 abiraterone 联合镭-223 治疗化疗初治去势抵抗性前列腺癌伴骨转移男性的 ERA 223 试验结果显示，无进展生存和无症状骨骼事件方面没有改善。我们假设这一发现可能归因于同时给予的泼尼松引起的骨丢失。

相似文献

1
Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit.镭-223 联合阿比特龙治疗的前列腺癌患者发生脆性骨折的风险更高：泼尼松可能是罪魁祸首。
Eur Urol. 2019 Jun;75(6):894-895. doi: 10.1016/j.eururo.2019.01.026. Epub 2019 Jan 31.
2
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.镭-223 联合醋酸阿比特龙和泼尼松或泼尼松龙治疗去势抵抗性前列腺癌和骨转移患者（ERA 223）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6.
3
A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study.镭-223 与安慰剂联合醋酸阿比特龙和泼尼松治疗去势抵抗性转移性前列腺癌的随机、双盲、对照研究：ERA 223 研究中日本患者的亚组分析。
Int J Clin Oncol. 2020 Apr;25(4):720-731. doi: 10.1007/s10147-019-01589-6. Epub 2019 Dec 10.
4
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).醋酸阿比特龙在未接受过化疗的转移性去势抵抗性前列腺癌患者中的更新中期疗效分析及长期安全性（COU-AA-302）
Eur Urol. 2014 Nov;66(5):815-25. doi: 10.1016/j.eururo.2014.02.056. Epub 2014 Mar 6.
5
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.醋酸阿比特龙联合泼尼松对比安慰剂联合泼尼松治疗化疗初治转移性去势抵抗性前列腺癌患者（COU-AA-302）：一项随机、双盲、安慰剂对照的 3 期研究的最终总生存分析。
Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16.
6
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.醋酸阿比特龙治疗初治转移性去势抵抗性前列腺癌患者时骨靶向治疗的影响：研究COU-AA-302的事后分析
Eur Urol. 2015 Oct;68(4):570-7. doi: 10.1016/j.eururo.2015.04.032. Epub 2015 May 16.
7
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.镭-223 联合阿比特龙或恩扎鲁胺治疗转移性去势抵抗性前列腺癌的真实世界评估。
PLoS One. 2021 Jun 21;16(6):e0253021. doi: 10.1371/journal.pone.0253021. eCollection 2021.
8
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.新诊断转移性去势敏感性前列腺癌患者中阿比特龙联合泼尼松添加到雄激素剥夺治疗后的患者报告结局（LATITUDE）：一项国际性、随机 3 期临床试验。
Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8.
9
Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.化疗初治转移性去势抵抗性前列腺癌患者接受恩扎卢胺或醋酸阿比特龙联合泼尼松治疗的经济学结局。
Adv Ther. 2020 May;37(5):2083-2097. doi: 10.1007/s12325-020-01260-x. Epub 2020 Feb 28.
10
Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?转移性去势抵抗性前列腺癌的联合治疗：我们能否通过添加镭-223 来安全提高疗效？
Cancer Biol Ther. 2020;21(1):1-3. doi: 10.1080/15384047.2019.1665395. Epub 2019 Sep 18.

引用本文的文献

1
The Tight Relationship Between the Tumoral Microenvironment and Radium-223.肿瘤微环境与镭-223之间的紧密关系
Biomedicines. 2025 Feb 12;13(2):456. doi: 10.3390/biomedicines13020456.
2
Nano-radiopharmaceuticals as therapeutic agents.纳米放射性药物作为治疗剂。
Front Med (Lausanne). 2024 Mar 15;11:1355058. doi: 10.3389/fmed.2024.1355058. eCollection 2024.
3
Zoledronic Acid Prevents Bone Resorption Caused by the Combination of Radium-223, Abiraterone Acetate, and Prednisone in an Intratibial Prostate Cancer Mouse Model.
唑来膦酸在胫骨内前列腺癌小鼠模型中可预防由镭-223、醋酸阿比特龙和泼尼松联合使用引起的骨吸收。
Cancers (Basel). 2023 Aug 15;15(16):4115. doi: 10.3390/cancers15164115.
4
Prognosis and safety of radium-223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration-resistant prostate cancer: Real-world data of Japanese patients.镭-223联合醋酸阿比特龙或恩杂鲁胺治疗转移性去势抵抗性前列腺癌的预后与安全性：日本患者的真实世界数据
BJUI Compass. 2020 Sep 5;2(1):31-38. doi: 10.1002/bco2.42. eCollection 2021 Jan.
5
Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice.接受激素剥夺疗法的癌症患者椎体骨折的预测：在实际临床实践中世界卫生组织骨折风险评估工具（FRAX）和骨密度的可靠性。
J Bone Oncol. 2022 Mar 9;33:100421. doi: 10.1016/j.jbo.2022.100421. eCollection 2022 Apr.
6
Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study.镭-223联合恩杂鲁胺治疗转移性去势抵抗性前列腺癌：一项多中心、II期开放标签研究。
Ther Adv Med Oncol. 2021 Sep 6;13:17588359211042691. doi: 10.1177/17588359211042691. eCollection 2021.
7
Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy.克服放射性药物治疗（RPT）的障碍：NRG-美国国立癌症研究所放射性药物治疗剂量学工作组概述
Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):905-912. doi: 10.1016/j.ijrobp.2020.12.002. Epub 2020 Dec 10.
8
Radiopharmaceutical therapy in cancer: clinical advances and challenges.放射性药物治疗癌症：临床进展与挑战。
Nat Rev Drug Discov. 2020 Sep;19(9):589-608. doi: 10.1038/s41573-020-0073-9. Epub 2020 Jul 29.
9
Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?转移性去势抵抗性前列腺癌的联合治疗：我们能否通过添加镭-223 来安全提高疗效？
Cancer Biol Ther. 2020;21(1):1-3. doi: 10.1080/15384047.2019.1665395. Epub 2019 Sep 18.